Fusion protein, recombinant vector, recombinant dendritic cell for transmembrane expression of novel coronavirus antigen S2, and application thereof
The invention provides a fusion protein, a recombinant vector, recombinant dendritic cells for transmembrane expression of novel coronavirus antigen S2, and application thereof, and belongs to the technical field of whole-cell vaccines. The fusion protein comprises a CD4 signal peptide, a novel coronavirus antigen S2 protein, a Flag tag sequence and a CD4 transmembrane domain which are linked in sequence; According to the invention, transmembrane cell expression is independently carried out on S2, ADE risks possibly caused by other S protein epitopes are avoided. The cell vaccine constructed by the fusion protein provided by the invention can induce higher neutralizing antibody titer in a mouse body..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 26. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
JIAO SHUNCHANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-02-26, Last update posted on www.tib.eu: 2022-04-10, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN112409496 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA011719761 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA011719761 | ||
| 003 | DE-627 | ||
| 005 | 20230503163724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210622s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA011719761 | ||
| 035 | |a (EPA)CN112409496 | ||
| 035 | |a (EPA)74842506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a JIAO SHUNCHANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fusion protein, recombinant vector, recombinant dendritic cell for transmembrane expression of novel coronavirus antigen S2, and application thereof |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-02-26, Last update posted on www.tib.eu: 2022-04-10, Last updated: 2023-02-09 | ||
| 520 | |a The invention provides a fusion protein, a recombinant vector, recombinant dendritic cells for transmembrane expression of novel coronavirus antigen S2, and application thereof, and belongs to the technical field of whole-cell vaccines. The fusion protein comprises a CD4 signal peptide, a novel coronavirus antigen S2 protein, a Flag tag sequence and a CD4 transmembrane domain which are linked in sequence; According to the invention, transmembrane cell expression is independently carried out on S2, ADE risks possibly caused by other S protein epitopes are avoided. The cell vaccine constructed by the fusion protein provided by the invention can induce higher neutralizing antibody titer in a mouse body. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHEN JINGYUAN |4 aut | |
| 700 | 0 | |a WANG KUNFU |4 aut | |
| 700 | 0 | |a YUAN HAN |4 aut | |
| 700 | 0 | |a ZHANG YANLING |4 aut | |
| 700 | 0 | |a LI SIHUI |4 aut | |
| 700 | 0 | |a FENG XIANGHUI |4 aut | |
| 700 | 0 | |a SONG WENJING |4 aut | |
| 700 | 0 | |a LYU PENGMIN |4 aut | |
| 700 | 0 | |a ZHONG HONGDONG |4 aut | |
| 700 | 0 | |a HU KUN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 26. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:26 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/74842506/publication/CN112409496A1?q=CN112409496 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 26 |c 02 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 26 |c 02 | ||